ABSTRACT
The number of annual THA's, TKA's, and TSA's is set to increase significantly by the year 2030, making it imperative to understand the risks for negative outcomes in these procedures. While research has studied the patient risk factors for perioperative and postoperative complications, there has been relatively little research for intraoperative complications. After a thorough literature review, the most supported finding was that patients with a BMI >30 had significantly more intraoperative blood loss than those with a BMI <30. All other relationships between patient risk factors and intraoperative complications of interest were inadequately studied.
Subject(s)
Arthroplasty, Replacement/adverse effects , Drug Interactions/genetics , Pain, Postoperative , Pharmacogenomic Testing , Pharmacogenomic Variants/genetics , ATP Binding Cassette Transporter, Subfamily B/genetics , Analgesics, Opioid/therapeutic use , Humans , Pain, Postoperative/drug therapy , Pain, Postoperative/geneticsSubject(s)
Arthroplasty, Replacement , Body Mass Index , Malnutrition , Nutritional Status/physiology , Preoperative Care/methods , Humans , Malnutrition/complications , Malnutrition/diagnosis , Nutrition Assessment , Postoperative Complications/etiology , Postoperative Complications/prevention & control , Treatment Outcome , Wound HealingSubject(s)
Analgesics, Opioid/pharmacology , Arthroplasty, Replacement, Hip , Arthroplasty, Replacement, Knee , Cytochrome P450 Family 3/pharmacology , Pain, Postoperative/prevention & control , Pharmacogenetics , Analgesics, Opioid/therapeutic use , Arthroplasty, Replacement, Hip/adverse effects , Arthroplasty, Replacement, Knee/adverse effects , Cytochrome P450 Family 3/therapeutic use , Humans , Pain Management , Pain, Postoperative/drug therapyABSTRACT
Eight patients with primary (n = 6) and metastatic (n = 2) disease of the liver underwent yttrium-90 radioembolization with glass microspheres using a combination of segmental and ipsilateral lobar approach to treat multifocal tumors containing a single dominant tumor. The superselective dose was administered to the dominant tumor, whereas lobar infusion was used for smaller tumors. Assuming uniform distribution, median dose to the segment with dominant tumor was 412.3 Gy and to the remaining lobe was 117.5 Gy. No instances of radiation-induced liver disease occurred. Combined segmental and ipsilateral lobar radioembolization is a well-tolerated procedure to treat unilateral multifocal hepatic tumors including a single dominant tumor.
